Annexon Says Phase 3 Study Of ANX005 In GBS Met Primary Goal
(RTTNews) – Annexon, Inc. (ANNX) on Tuesday said that the Phase 3 trial of ANX005 in patients with Guillain-Barre syndrome (GBS) met its primary goal. GBS is a rare auto immune disorder affecting the nerves.